s6y

Medicus Pharma Ltd.

Ticker
MDCX, MDCXW
CIK
1997296
Industry
Pharmaceutical Preparations

Financials 10

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K/A Annual Report for period ending Dec 31, 2025
  5. 10-K Annual Report for period ending Dec 31, 2025
  6. 10-Q Quarterly Report for period ending Sep 30, 2025
  7. 10-Q Quarterly Report for period ending Jun 30, 2025
  8. 10-Q Quarterly Report for period ending Mar 31, 2025
  9. 10-K/A Annual Report for period ending Dec 31, 2024
  10. 10-K Annual Report for period ending Dec 31, 2024

News 38

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 38 news filings

Ownership 92

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 92 ownership filings

Prospectus 120

  1. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  2. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  3. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  4. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
  5. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
  6. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  7. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
  8. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  9. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  10. 424B3 Prospectus filed pursuant to Rule 424(b)(3)

All 120 prospectus filings

Proxies 7

  1. DEF 14A Definitive proxy statements
  2. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  3. DEF 14A Definitive proxy statements
  4. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  5. DEF 14A Definitive proxy statements
  6. PRER14A Preliminary revised proxy soliciting materials
  7. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition

Other 95

  1. SCHEDULE 13D/A
  2. SCHEDULE 13G/A
  3. SCHEDULE 13D
  4. SCHEDULE 13G/A
  5. ARS Annual report to security holders
  6. EFFECT Notice of Effectiveness
  7. EFFECT Notice of Effectiveness
  8. EFFECT Notice of Effectiveness
  9. POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing
  10. POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing

All 95 other filings